20.4 C
New York
Thursday, June 18, 2026

Tag: description

newssourceFORcompanyinformationcontent1marketreleases

CD40/CD40L Inhibitors Market on Growth Trajectory Driven by Advancements in Autoimmune and Cancer Therapeutics | DelveInsight

The CD40/CD40L inhibitors market is experiencing steady growth driven by increasing research into autoimmune diseases, organ transplantation, and cancer immunotherapy. The rising prevalence of...

CD40/CD40L Inhibitors Market on Growth Trajectory Driven by Advancements in Autoimmune and Cancer Therapeutics | DelveInsight

The CD40/CD40L inhibitors market is experiencing steady growth driven by increasing research into autoimmune diseases, organ transplantation, and cancer immunotherapy. The rising prevalence of...

B7-H4 Targeting Therapies Market Growth Set to Accelerate Across the 7MM During the Study Period (2025-2040) with Advances in Immunotherapy | DelveInsight

The market for B7-H4 targeted therapies is projected to experience substantial growth in the coming years, driven by a rising incidence of cancer diagnoses,...

B7-H4 Targeting Therapies Market Growth Set to Accelerate Across the 7MM During the Study Period (2025-2040) with Advances in Immunotherapy | DelveInsight

The market for B7-H4 targeted therapies is projected to experience substantial growth in the coming years, driven by a rising incidence of cancer diagnoses,...

Ovintiv Reports Second Quarter 2025 Financial and Operating Results

Full Year Capital Guidance Lowered; Production Guidance Increased Highlights: Generated cash from operating activities of $1,013 million, Non-GAAP Cash Flow of $913 million and Non-GAAP Free...

GLOBAL X ANNOUNCES JULY 2025 DISTRIBUTIONS FOR ITS SUITE OF ETFs

TORONTO, July 24, 2025 /CNW/ - Global X Investments Canada Inc. ("Global X") is pleased to announce the distribution amounts per security (the "Distributions") for...

Ovintiv Reports Second Quarter 2025 Financial and Operating Results

Full Year Capital Guidance Lowered; Production Guidance Increased Highlights: Generated cash from operating activities of $1,013 million, Non-GAAP Cash Flow of $913 million and Non-GAAP Free...

Archrock Increases Quarterly Cash Dividend

HOUSTON, July 24, 2025 (GLOBE NEWSWIRE) -- Archrock, Inc. (NYSE: AROC) (“Archrock” or the “Company”) today announced that its Board of Directors has declared an increased quarterly dividend of $0.21 per share of common stock, or $0.84 per share on an annualized basis. The second quarter 2025 dividend will be paid on August 12, 2025 to all stockholders of record on August 5, 2025.

IDEAYA Biosciences Announces Proffered Paper Oral Presentation at ESMO 2025 for Phase 2 Clinical Trial of Neoadjuvant Darovasertib in Primary Uveal Melanoma

The presentation will include data from over 90 patients in both the plaque brachytherapy and enucleation-eligible cohortsDarovasertib has received U.S. FDA Breakthrough Therapy Designation...

Form 8.3 – Marlowe plc – Octopus Investments

FORM 8.3

Dimensional Fund Advisors Ltd. : Form 8.3 – EMPIRIC STUDENT PROPERTY PLC – Ordinary Shares

FORM 8.3

Form 8.5 (EPT/RI) – Dowlais Group plc

FORM 8.5 (EPT/RI)

Claudin 18.2-Directed Oncology Therapeutics–A Fast-Growing Market with Blockbuster Potential | DelveInsight

Claudin 18.2-directed therapies are on track to become foundational in the treatment of gastrointestinal and select solid tumors. Fueled by innovation in antibody engineering,...

Claudin 18.2-Directed Oncology Therapeutics–A Fast-Growing Market with Blockbuster Potential | DelveInsight

Claudin 18.2-directed therapies are on track to become foundational in the treatment of gastrointestinal and select solid tumors. Fueled by innovation in antibody engineering,...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsDescription

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers